Jan R.H. Hanauer

DARPin-targeting of Measles Virus: Unique Bispecificity, Effective Oncolysis, and Enhanced Safety

Katrin Friedrich, Jan R.H. Hanauer, Steffen Prüfer et al. · Molecular Therapy · 2013 · 71 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model

Bianca S. Bodmer, Anna H. Fiedler, Jan R.H. Hanauer et al. · Virology · 2018 · 47 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles

Stefan Hutzler, Stephanie Erbar, Robert A. Jabulowsky et al. · Scientific Reports · 2017 · 27 citations · Full text

Life Sciences, Medicine, Immunology +18

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2 /neu or EpCAM as target receptors

Jan R.H. Hanauer, Lisa Gottschlich, Dennis Riehl et al. · Molecular Therapy — Oncolytics · 2016 · 22 citations · Full text

Medicine, Cancer Biology, Oncology +17

High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency

Jan R.H. Hanauer, Vivian Koch, Ulrich M. Lauer et al. · Molecular Therapy — Oncolytics · 2019 · 15 citations · Full text

Medicine, Biotechnology, Oncology +17